Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Oral Hypoglyceimic Agents (OHAs) Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Oral Hypoglyceimic Agents (OHAs) Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Sulfonylureas
      • 1.3.3 Metformin
      • 1.3.4 Thiazolidinediones
      • 1.3.5 Alpha-Glucosidase Inhibitors
    • 1.4 Market Segment by Application
      • 1.4.1 Global Oral Hypoglyceimic Agents (OHAs) Market Share by Application (2019-2025)
      • 1.4.2 Hospitals and Clinics
      • 1.4.3 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Oral Hypoglyceimic Agents (OHAs) Market Size
      • 2.1.1 Global Oral Hypoglyceimic Agents (OHAs) Revenue 2014-2025
      • 2.1.2 Global Oral Hypoglyceimic Agents (OHAs) Sales 2014-2025
    • 2.2 Oral Hypoglyceimic Agents (OHAs) Growth Rate by Regions
      • 2.2.1 Global Oral Hypoglyceimic Agents (OHAs) Sales by Regions 2014-2019
      • 2.2.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Oral Hypoglyceimic Agents (OHAs) Sales by Manufacturers
      • 3.1.1 Oral Hypoglyceimic Agents (OHAs) Sales by Manufacturers 2014-2019
      • 3.1.2 Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Oral Hypoglyceimic Agents (OHAs) Revenue by Manufacturers (2014-2019)
      • 3.2.2 Oral Hypoglyceimic Agents (OHAs) Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Oral Hypoglyceimic Agents (OHAs) Market Concentration Ratio (CR5 and HHI)
    • 3.3 Oral Hypoglyceimic Agents (OHAs) Price by Manufacturers
    • 3.4 Key Manufacturers Oral Hypoglyceimic Agents (OHAs) Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Oral Hypoglyceimic Agents (OHAs) Market
    • 3.6 Key Manufacturers Oral Hypoglyceimic Agents (OHAs) Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Sulfonylureas Sales and Revenue (2014-2019)
      • 4.1.2 Metformin Sales and Revenue (2014-2019)
      • 4.1.3 Thiazolidinediones Sales and Revenue (2014-2019)
      • 4.1.4 Alpha-Glucosidase Inhibitors Sales and Revenue (2014-2019)
    • 4.2 Global Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Type
    • 4.3 Global Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Type
    • 4.4 Oral Hypoglyceimic Agents (OHAs) Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Oral Hypoglyceimic Agents (OHAs) Sales by Application

    6 United States

    • 6.1 United States Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Company
    • 6.2 United States Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Type
    • 6.3 United States Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Application

    7 European Union

    • 7.1 European Union Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Company
    • 7.2 European Union Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Type
    • 7.3 European Union Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Application

    8 China

    • 8.1 China Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Company
    • 8.2 China Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Type
    • 8.3 China Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Company
    • 9.2 Rest of World Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Type
    • 9.3 Rest of World Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Application
    • 9.4 Rest of World Oral Hypoglyceimic Agents (OHAs) Breakdown Data by Countries
      • 9.4.1 Rest of World Oral Hypoglyceimic Agents (OHAs) Sales by Countries
      • 9.4.2 Rest of World Oral Hypoglyceimic Agents (OHAs) Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Pfizer
      • 10.1.1 Pfizer Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.1.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.1.5 Pfizer Recent Development
    • 10.2 GlaxoSmithKline
      • 10.2.1 GlaxoSmithKline Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.2.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.2.5 GlaxoSmithKline Recent Development
    • 10.3 Bayer
      • 10.3.1 Bayer Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.3.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.3.5 Bayer Recent Development
    • 10.4 Bristol-Myers Squibb
      • 10.4.1 Bristol-Myers Squibb Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.4.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.4.5 Bristol-Myers Squibb Recent Development
    • 10.5 Novonordisk
      • 10.5.1 Novonordisk Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.5.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.5.5 Novonordisk Recent Development
    • 10.6 Sanofi-Aventis
      • 10.6.1 Sanofi-Aventis Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.6.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.6.5 Sanofi-Aventis Recent Development
    • 10.7 Servier
      • 10.7.1 Servier Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.7.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.7.5 Servier Recent Development
    • 10.8 Huadong Medicine
      • 10.8.1 Huadong Medicine Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.8.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.8.5 Huadong Medicine Recent Development
    • 10.9 Wanbang Biopharmaceuticals
      • 10.9.1 Wanbang Biopharmaceuticals Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.9.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.9.5 Wanbang Biopharmaceuticals Recent Development
    • 10.10 Double-Crane Pharmaceutical
      • 10.10.1 Double-Crane Pharmaceutical Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Oral Hypoglyceimic Agents (OHAs)
      • 10.10.4 Oral Hypoglyceimic Agents (OHAs) Product Introduction
      • 10.10.5 Double-Crane Pharmaceutical Recent Development
    • 10.11 Guangzhou Pharmaceutical

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Oral Hypoglyceimic Agents (OHAs) Sales Channels
      • 11.2.2 Oral Hypoglyceimic Agents (OHAs) Distributors
    • 11.3 Oral Hypoglyceimic Agents (OHAs) Customers

    12 Market Forecast

    • 12.1 Global Oral Hypoglyceimic Agents (OHAs) Sales and Revenue Forecast 2019-2025
    • 12.2 Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Type
    • 12.3 Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Application
    • 12.4 Oral Hypoglyceimic Agents (OHAs) Forecast by Regions
      • 12.4.1 Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Oral hypoglycemic agents (OHAs) are a group of drugs used to help reduce the amount of sugar present in the blood. They are not insulin, but they stimulate the pancreas to produce insulin.
      At present, China is a country with the most populous victims of diabetes, SO, China will witness a huge potential in the OHAS market.
      In 2019, the market size of Oral Hypoglyceimic Agents (OHAs) is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Oral Hypoglyceimic Agents (OHAs).

      This report studies the global market size of Oral Hypoglyceimic Agents (OHAs), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Oral Hypoglyceimic Agents (OHAs) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Pfizer
      GlaxoSmithKline
      Bayer
      Bristol-Myers Squibb
      Novonordisk
      Sanofi-Aventis
      Servier
      Huadong Medicine
      Wanbang Biopharmaceuticals
      Double-Crane Pharmaceutical
      Guangzhou Pharmaceutical

      Market Segment by Product Type
      Sulfonylureas
      Metformin
      Thiazolidinediones
      Alpha-Glucosidase Inhibitors

      Market Segment by Application
      Hospitals and Clinics
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Oral Hypoglyceimic Agents (OHAs) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Oral Hypoglyceimic Agents (OHAs) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Oral Hypoglyceimic Agents (OHAs) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now